ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO315

A Novel Role of APOL1 Risk-Alleles in T-Cell Activation and Focal Segmental Glomerulosclerosis

Session Information

Category: Genetic Diseases of the Kidneys

  • 1102 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Pell, John F., Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Reghuvaran, Anand, Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Nagata, Soichiro, Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Banu, Khadija, Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Shi, Hongmei, Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Chernova, Irene, Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Ishibe, Shuta, Yale University Department of Internal Medicine, New Haven, Connecticut, United States
  • Menon, Madhav C., Yale University Department of Internal Medicine, New Haven, Connecticut, United States
Background

G1-, G2-variants in apolipoprotein-L1 (APOL1) increase the risk of FSGS vs. the major allele (G0). While podocyte APOL1 expression is needed for FSGS, we recently reported a provocative role for APOL1 within the immune system, as activated CD4+ and CD8+ T cells which expressed APOL1 showed more activation in G1- or G2-genotypes by single cell transcriptomics.

Methods

We studied APOL1’s immunological role using a novel BAC-transgenic mouse (BAC-Tg) for G0-, G1- or G2-APOL1 expression under the human APOL1 promoter (G0-, G1-, G2-pure), and crossed each BAC-Tg line with dox-inducible interferon γ (Ifng)-expressing mice (either Rosa-Ifng- or Nphs2-Ifng-G0,-G1, or -G2), as IFNγ regulates APOL1 expression.

Results

In splenocytes, APOL1- and dox-induced IFNγ-expression were confirmed by qPCR. FACS analysis showed that adult BAC-Tg spleens had similar proportions of major immune cell types in all variants with/without dox. The proportion of CD8+ T cells that were activated (CD44+CD8+) was significantly higher in G1 and G2 mice following dox vs. G0 [Fig.A-B]. T cell receptor stimulated G1-, G2-CD8+ T cells showed greater proliferation and marked IFNγ production vs. G0 [C-D]. In response to viral nucleic acid, G1-CD8+ T cells showed further increases in IFNγ and IL-2 intracellular staining (P<0.01 vs G0).
To test the role of APOL1-variant immune cells in FSGS, we used bone marrow transfer [E]. Rosa-Ifng-G1, -G2 mice that received Rosa-Ifng-G1-marrow developed FSGS after dox feeding (positive control). Strikingly, Ifng-G1 marrow (IFNγ induced only in donor cells) induced albuminuria in G1-, G2-pure recipients (without podocyte IFNγ excess) while Nphs2-driven IFNγ expression did not induce FSGS, suggesting FSGS was induced in variant-glomeruli by G1-marrow-derived IFNγ [F-G; n=4]. Ex vivo, primary G1-podocytes treated with supernatant from TCR-stimulated G1-CD8+ T cells showed greater apoptosis (Annexin V) vs. G0 supernatant [n=3 each; H].

Conclusion

Our data suggest a novel role for activated CD8+ T cells as a key source of IFNγ in G1- and G2 risk-genotype-Bac-Tg mice, inducing FSGS.

Funding

  • Other NIH Support